Infant Formula Factory Setup in Indonesia: Entity, Industrial Site, and Approvals

Freeze the infant formula product and process basis

An infant formula project cannot be scoped from the words “milk powder factory.” The investment basis must identify the product category, intended age group, whether the formula serves ordinary or special medical needs, complete composition, pack format, expected shelf life and manufacturing method. Powdered infant formula, follow-on formula, growing-up formula and ready-to-feed products do not automatically share the same technical or product requirements.

Define whether the Indonesian site will use a wet-mix process with heat treatment and drying, a dry-mix process, a combined process with post-heat additions, or only a narrowly defined packing operation. This choice changes the utility load, high-hygiene boundary, water and drainage philosophy, raw-material controls, validation plan and environmental profile. It also determines whether a candidate warehouse can realistically become the proposed factory.

The controlled project brief should state the exact product and process boundary , not a future catalogue of every food the investor may someday make. Include the designed batch range, annual capacity, dairy and non-dairy inputs, allergen profile, micronutrient dosing, rework policy, packaging atmosphere, testing model, cold or ambient storage and any imported intermediate. Mark every open assumption and the date by which it must be closed.

Establish the operator under current KBLI 10791

The current OSS entry for KBLI 2025 10791 is titled the baby food and special food industry. Its description expressly includes infant formula, follow-on products, growing-up formula, complementary foods, homogenised baby foods, products for pregnant or breastfeeding women and foods for particular medical needs. OSS also records that two former classifications were merged into 10791 for KBLI 2025, so a legacy code analysis must be converted rather than copied.

The entity should be established for the actual manufacturing and applicant role. For a foreign-investment company, test the exact KBLI and product scope under Presidential Regulation 49/2021 and its current schedules. KBLI 10791 is not named in the domestic-capital-only list in Annex III , which supports assessing a PT PMA route, but the project must still confirm any sector condition, scale rule, location condition and current OSS implementation before relying on that conclusion.

Align the deed and AHU record with the OSS business profile, tax identity, beneficial-owner data, NIB, five-digit KBLI, project location and declared capacity. The company that controls the facility and appears in sector submissions must be clear. If a brand owner, land company and manufacturer are different parties, contracts should allocate site control, dossier access, batch release, inspection access, complaints and recall duties; an informal group-company arrangement is not a regulatory evidence chain.

The general company steps can be reviewed under Indonesia company registration requirements . Keep that layer distinct from permission to construct, occupy, manufacture or sell. An issued NIB identifies the business in OSS but does not, by itself, show that the premises meet infant-formula controls or that any product has BPOM authorisation.

• Use the actual factory address in the licence dependency register, including building or plot identifiers used by local systems.
• Reconcile shareholder eligibility before signing arrangements that assume the PT PMA can operate the selected activity.
• Document the legal applicant for CPPOB, risk-management, product and other supporting services.
• Create a controlled corporate-data sheet so every portal submission uses identical names, addresses and identifiers.

Apply a pre-lease veto to the industrial site

A candidate site should fail quickly if a legal or technical constraint cannot be cured within the investment case. Begin with evidence of title or the landlord’s lawful control, parcel boundaries, permitted industrial use, access rights, estate rules, existing buildings and encumbrances. Match the proposed KBLI and capacity to the spatial result and to any estate or local limitation. A lease description such as “food grade” is not an official land-use or facility approval.

Government Regulation 28/2025 now governs Indonesia’s risk-based business licensing framework and replaced the earlier PP 5/2021 regime. The outputs depend on the activity, risk, scale, location and data entered. Obtain the project-specific OSS result and list every standard, licence and supporting approval it triggers; do not rely on a risk level quoted for another factory or for a former KBLI version.

Environmental approval must be based on the real process and capacity. Under Government Regulation 22/2021 , assess the applicable environmental instrument and technical approvals or standards for water, wastewater, emissions, waste, hazardous materials and other impacts. A wet-mix and spray-drying facility can have materially different water, energy, air and effluent loads from a dry-blend operation. Test utility availability and discharge acceptance against measured capacity, not a landlord’s verbal assurance.

The building path is separate. Government Regulation 16/2021 is the building-regulation framework for PBG and functional fitness. Verify whether the existing approval and stated building function cover the factory and the intended alteration, fire strategy, loading, silos, mezzanines, laboratories and utilities. Plan the PBG change or new application before construction and the SLF evidence before use, using the locally competent process and SIMBG.

Reject the site when an unresolved legal, utility or hygiene constraint would require the approved process to be materially different from the investment basis. Conditions precedent should state the document, issuing party, acceptable result, deadline and exit right. A vague promise to “assist with permits” is not a condition that protects capital.

Translate powdered-formula microbial risk into the layout

Powdered formula is not sterile, so the site must prevent introduction and persistence of hazards after any lethality step. The Codex Code of Hygienic Practice for Powdered Formulae for Infants and Young Children focuses on Salmonella and Cronobacter species. It distinguishes wet-mix, dry-mix and combined processes and recommends strict separation of wet and dry areas, protection of high-hygiene areas, control of people, material and equipment movement, and prevention of condensation and harbourage.

Draw the site from the most sensitive product zone outward. Operations from drying through filling and hermetic closure require a protected strategy appropriate to the process. Locate personnel change, material airlocks, packaging entry, maintenance access, waste removal and sample transfer so they do not bypass the barrier. Air-handling design should preserve zoning; the building envelope and service penetrations should be accessible, cleanable and resistant to condensation.

Water is useful in wet processing but hazardous when it enters a dry high-care environment. Limit water distribution in the dry high-hygiene zone , avoid unnecessary drains, and design controlled cleaning and rapid drying for cases where wet cleaning cannot be avoided. Roof leaks, chilled-service condensation and poorly placed handwashing or fire systems must be considered during design rather than discovered during qualification.

The national approval dossier and the facility’s own hazard analysis remain controlling; Codex is used here as a design and verification reference, not as a substitute for Indonesian requirements. Convert each risk into a user requirement, drawing reference, acceptance criterion and test. This makes the hygiene concept inspectable and prevents value engineering from removing a control whose regulatory purpose was never recorded.

Build the factory approval critical path

The critical path should show which final output unlocks the next irreversible act. The entity and KBLI support the OSS project. Spatial and environmental results constrain the layout. PBG governs the approved construction or alteration basis, while functional fitness evidence supports lawful use. The food-facility workstream then addresses CPPOB and any applicable risk-management approval. Product registration depends on an eligible applicant, a qualified site and a stable formula and label.

The current OSS page for 10791 lists supporting services including processed-food authorisation, CPPOB, approval for the processed-food production risk-management program and a service for processed food subject to mandatory SNI. That list is a routing signal, not proof that every service applies identically to every formula. Confirm the live service, product trigger, issuing authority, prerequisites and exact output for the proposed process.

Track standards as an applicability decision. Identify the exact product, current Indonesian standard and current mandatory instrument, if any; then verify the required conformity-assessment body, sampling, factory assessment, certificate holder, mark and linkage to BPOM. Do not claim an SNI obligation merely because OSS displays a generic service, and do not assume voluntary conformity replaces BPOM product approval.

Maintain one register showing official service name, applicant, site, product or process scope, portal number, payment, dependencies, question owner, issue date, conditions, validity and renewal lead time. Close a gate with final issued evidence , not a screenshot of “submitted,” an appointment notice or a consultant’s progress statement. Changes to capacity, layout, process, company data or formula should automatically identify the records that require amendment.

Prove the formula, label, and market route

BPOM Regulation 1/2018 governs processed food for special nutritional purposes and remains listed as effective, with changes including BPOM Regulation 24/2020 . It consolidated prior formula-specific controls identified in its status history. Use the consolidated current text for the intended infant, follow-on or medical-purpose product rather than extracting one historic requirement in isolation.

The product dossier should reconcile the quantitative formula, ingredient identity and source, compositional and purity requirements, manufacturing process, hazard controls, specifications, methods, stability, packaging, instructions, warnings and label. Post-heat additions require special attention because supplier control and entry into the high-hygiene zone become part of the product-safety argument. The approved formula must be the formula used in the master manufacturing record.

BPOM Regulation 23/2023 is the processed-food registration framework. Create one comparison sheet between the submitted dossier, BPOM questions, final authorisation, approved artwork and factory master data. A product number is not a transferable permission for a different manufacturer, composition, age range, pack or label; route changes through the applicable variation or new-registration analysis before implementation.

Keep marketing permission outside the engineering assumption set

Approval to manufacture does not confer unrestricted promotion. The Ministry of Health’s explanation of infant-formula rules under Government Regulation 28/2024 describes controls directed at producers and distributors of infant formula and breast-milk substitutes. Legal and regulatory review should approve the launch plan, interactions with health facilities and professionals, promotions, samples, discounts, cross-promotion and educational material separately from the plant’s product-release decision.

Create a market-release packet containing the valid BPOM output, exact approved label, applicable conformity and halal evidence, distribution conditions, traceability format, complaint contacts and recall decision tree. Preparation instructions and batch identification should be tested for clarity and recall use. Sales forecasts do not authorise advance production beyond what the approved shelf-life, facility scope and controlled release system can support.

Commission the factory as an evidence system

Mechanical completion is only the starting point. Commission utilities in a sequence that protects clean systems from construction contamination, then qualify rooms, air handling, water where used, compressed gases, dust control, cleaning systems, laboratory equipment, blending, drying, transfer, filling and closure equipment. Calibrate instruments and establish maintenance access without breaking the hygiene barrier. Preserve deviations and corrective evidence rather than rewriting protocols after a failed test.

The environmental monitoring program should be risk-based and connected to zoning, traffic, harbourage and the organisms relevant to powdered formula. Define locations, frequency, methods, alert or action logic, escalation, product impact and intensified follow-up. Challenge the program during maintenance, construction, water events and unusual interventions. Trend data across time and space so a weak signal is not dismissed as an isolated result.

1. Verify installation against approved drawings, equipment specifications and hygienic-design requirements.
2. Challenge personnel, ingredient, packaging, waste and maintenance flows at operating pace.
3. Demonstrate cleaning, drying, line clearance, allergen control and prevention of unauthorised rework.
4. Qualify sampling and analytical methods, laboratory data integrity and out-of-specification handling.
5. Run process and packaging trials across justified operating ranges without releasing saleable stock prematurely.
6. Complete mock traceability and recall, including supplier-to-batch and batch-to-customer reconciliation.

Assemble the turnover file by approval assertion: drawing, test, result, deviation, corrective action, approver and final status. Link the facility scope to each launch SKU and identify conditions that operations must maintain. The related guide to the commissioning evidence gate for Indonesian factories adds broader context; the infant-formula file should go further by proving the high-hygiene boundary and product-specific release chain.

Release authority should sit with a named quality role independent enough to hold a batch or stop a line. That role needs current licence visibility, not only laboratory results. A conforming batch produced after a facility certificate expires, at an unapproved line or under changed artwork is not commercially releasable merely because its analytical tests pass.

Decide whether to acquire, redesign, or reject the site

Acquire the site only when the entity can lawfully operate KBLI 10791, the parcel and building have a documented approval path, utilities support the frozen process, the layout protects post-lethality handling, and the BPOM facility and product route can be completed for the launch formula. The decision paper should name every residual risk, owner, deadline, cost allowance and contractual protection.

Redesign is preferable to disguising a mismatch. A warehouse can become a different, lawfully approved plant only after the new process and building path are assessed; a packing operation cannot be described as full manufacture when critical production occurs elsewhere. Contract manufacture may be a rational launch route, but the chosen manufacturer must hold the correct facility scope and grant the brand owner access to the data needed for registration, change assessment and recall.

Proceed only when one controlled evidence chain connects the company, parcel, building, process, facility approval, product authorisation and batch release. If any link relies on a future verbal assurance, keep the project conditional or stop it. That discipline protects both the investment and the infants for whom manufacturing failure carries the highest consequence.